journal cover

Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis

AIDS

Nov 15, 2019

Tammy M MeyersIMPAACT P1101 Team

Get paper from

Abstract

Drug-drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and well tolerated do...read more

Mentioned in this Paper

Hepatitis
HIV Infections
Rifampin
Treatment Protocols
Tuberculosis
Glucuronosyltransferase
Pharmacokinetic Study
Site
Coinfection
Human immunodeficiency virus 1 RNA
4
4
1
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

HIV & Co-Infections

HIV co-infection worsens the histological course of other viral infections, such as HCV by increasing and accelerating the risk of cirrhosis or leading to rare but lethal fibrosing cholestatic hepatitis. Discover the latest research on HIV co-infection.

AIDS Malignancies

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV: Cell & Gene Therapy

This feed focuses on emerging cell and gene therapies, such as HIV vaccines, for treating patients living with HIV/AIDS. Discover the latest research here.

Tuberculosis

Tuberculosis is an infectious disease usually caused by Mycobacterium tuberculosis bacteria. Discover the latest research on tuberculosis here.

© 2019 Meta ULC. All rights reserved

Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis

AIDS

Nov 15, 2019

Tammy M MeyersIMPAACT P1101 Team

PMID: 31689263

DOI: 10.1097/qad.0000000000002369

Abstract

Drug-drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and well tolerated do...read more

Mentioned in this Paper

Hepatitis
HIV Infections
Rifampin
Treatment Protocols
Tuberculosis
4
4
1

Related Papers

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/pharmacokinetics-and-safety-of-a-raltegravir-conta/31689263